	US 12,011,470 B2
	Micelle preparations of full-spectrum hemp oil
Clint Sorensen, St. George, UT (US); Melanie Montgomery, Scottsdale, AZ (US); and Matt Smith, Highland, UT (US)
Filed by Clint Sorensen, St. George, UT (US); Melanie Montgomery, Scottsdale, AZ (US); and Matt Smith, Highland, UT (US)
Filed on Mar. 31, 2022, as Appl. No. 17/711,014.
Application 17/711,014 is a continuation of application No. 17/388,061, filed on Jul. 29, 2021, abandoned.
Application 17/388,061 is a continuation of application No. PCT/US2021/071038, filed on Jul. 28, 2021.
Prior Publication US 2023/0038771 A1, Feb. 9, 2023
Int. Cl. A61K 36/185 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 31/05 (2006.01); A61K 31/352 (2006.01); A61P 25/20 (2006.01)

CPC A61K 36/185 (2013.01) [A61K 9/0053 (2013.01); A61K 9/1075 (2013.01); A61K 31/05 (2013.01); A61K 31/352 (2013.01); A61P 25/20 (2018.01)]

11 Claims

1. A therapeutic preparation of full spectrum hemp oil formulated for oral administration to a human subject,

comprising 0.1% cannabinoids as a percent by weight of the preparation;

wherein at least 80% of the cannabinoids in the preparation are in the form of micelles suspended in an aqueous solvent;

wherein the cannabinoids comprise the following: at least 70% cannabidiol (CBD), at least 2% tetrahydrocannabivarin (THCV), at least 5% cannabidivarin (CBDV), and less than 1% Δ9-tetrahydrocannabinol (THC) as a percent by weight of the cannabinoids in the preparation;

wherein the micelles in the preparation have a median diameter between 10 and 100 nm;

wherein the micelles in the preparation are sized and formulated to promote intestinal absorption of the cannabinoids into the subject, whereby 25% to 50% or more of the cannabinoids from the preparation reach the circulation within 6 hours of oral administration.